Raymond James Financial Inc. Has $19.25 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Raymond James Financial Inc. increased its position in Jazz Pharmaceuticals by 67.9%, owning 155,066 shares valued at approximately $19.25 million after acquiring an additional 62,719 shares in the first quarter.
• Jazz Pharmaceuticals reported a loss of $8.25 per share in its latest quarterly earnings, missing consensus estimates, while its annual revenue showed a modest year-over-year increase of 2.1%.
• Insider trades indicate ongoing confidence in the company, with CEO Bruce C. Cozadd recently selling 1,000 shares but still retaining a significant ownership position valued around $47 million.

Raymond James Financial Inc. increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 67.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 155,066 shares of the specialty pharmaceutical company's stock after acquiring an additional 62,719 shares during the period. Raymond James Financial Inc. owned about 0.25% of Jazz Pharmaceuticals worth $19,251,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of JAZZ. Hurley Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals during the first quarter worth $25,000. Elequin Capital LP raised its holdings in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares in the last quarter. Parallel Advisors LLC raised its holdings in Jazz Pharmaceuticals by 85.6% during the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after buying an additional 119 shares in the last quarter. Picton Mahoney Asset Management raised its holdings in Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after buying an additional 269 shares in the last quarter. Finally, Spire Wealth Management raised its holdings in Jazz Pharmaceuticals by 137.6% during the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after buying an additional 161 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the sale, the chief executive officer directly owned 436,973 shares of the company's stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Morgan Stanley raised their target price on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a report on Thursday, August 28th. The Goldman Sachs Group raised their target price on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a report on Friday. Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Piper Sandler restated an "overweight" rating and set a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Finally, Truist Financial raised their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $178.67.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded up $1.91 during midday trading on Tuesday, hitting $129.66. The company's stock had a trading volume of 879,041 shares, compared to its average volume of 874,642. The stock has a market capitalization of $7.87 billion, a price-to-earnings ratio of -19.27, a PEG ratio of 8.04 and a beta of 0.24. The stock's 50 day simple moving average is $115.33 and its 200 day simple moving average is $117.02. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.